PARTNER 3试验低危患者外科主动脉瓣置换五年结局
PARTNER 3试验中454例低危重度症状性三叶式主动脉瓣狭窄患者接受外科主动脉瓣置换(SAVR),其中孤立SAVR 334例、合并手术SAVR 120例,随访5年。再干预率低,多数患者无生物瓣膜衰败证据。
要点
- 低危患者SAVR五年全因死亡率9.0%,孤立与合并手术组无显著差异。
- 五年再干预率孤立SAVR 2.3%、合并SAVR 5.0%,均较低。
- 多数患者五年时存活且无生物瓣膜衰败证据。
核心结论
- PARTNER 3试验低危患者SAVR五年结局良好,孤立与合并手术组死亡率相似。
- 结果与近期全国SAVR结局相当,提示结论具有普遍性。
研究设计与样本
- PARTNER 3随机试验中接受外科主动脉瓣置换的454例低危重度症状性三叶式主动脉瓣狭窄患者,随访5年。
- 按孤立SAVR(n=334,73.6%)与合并手术SAVR(n=120,26.4%)分层。
- 临床事件委员会裁定短期和长期发病率,超声核心实验室评估瓣膜血流动力学,KCCQ测量患者报告健康状况。
主要发现
- 平均年龄73.6±6.1岁,男性占71.1%,SAVR植入尺寸中位数总体为23 mm。
- 五年平均跨瓣压差总体11.7±5.6 mm Hg。
- 五年时无生物瓣膜衰败且存活者比例孤立SAVR 87.9%、合并SAVR 86.1%。
关键数值与推荐
- 五年全因死亡率与近期STS数据库低危孤立SAVR分析(总体死亡率7.1%)相当。
临床怎么用
- 低危重度症状性三叶式主动脉瓣狭窄患者行SAVR可获得良好的五年生存与瓣膜耐久性。
- 合并手术未显著增加五年死亡或再干预风险,支持合理选择合并手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery remains an important treatment for low-risk patients with severe symptomatic aortic stenosis (AS). This study evaluated 5-year outcomes in low-risk patients undergoing isolated surgical aortic valve replacement (SAVR) or SAVR with concomitant procedures within the randomized Placement of Aortic Transcatheter Valves (PARTNER) 3 trial. METHODS: In the PARTNER 3 trial, 454 patients underwent surgery for severe, symptomatic, trileaflet AS and were followed up for 5 years. Patients were stratified into those undergoing isolated SAVR (n = 334; 73.6%) vs concomitant SAVR (n = 120; 26.4%). Short- and long-term morbidity was adjudicated by a Clinical Events Committee. Hemodynamic valve performance was evaluated by an echocardiographic core laboratory. Patient-reported health status was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: The mean age of participants was 73.6 ± 6.1 years; 71.1% of these patients were male. The median SAVR implant size was 23 mm overall. Five-year all-cause mortality (with vital status sweep) was 9.0% for all patients (8.5% isolated SAVR; 10.2% concomitant SAVR; P = .58), comparable to a recent analysis of low-risk isolated SAVR-treated patients in the STS database (overall mortality, 7.1%). The average 5-year mean gradient was 11.7 ± 5.6 mm Hg overall. Reintervention rates were low in both groups (isolated SAVR, 2.3% vs concomitant SAVR, 5.0%; P = .21), and most patients (isolated SAVR, 87.9%; concomitant SAVR, 86.1%) were alive with no evidence of bioprosthetic valve failure at 5 years. CONCLUSIONS: SAVR in low-risk patients in the PARTNER 3 trial demonstrated excellent 5-year outcomes. Five-year mortality was similar in patients undergoing isolated SAVR vs concomitant SAVR. This result was comparable to recently published national SAVR outcomes, thus demonstrating the generalizability of these findings.
引用
- Thourani VH, Leon MB, Makkar R, et al. Five- Year Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial. Ann Thorac Surg. 2024. PMID: 39694217. doi:10.1016/j.athoracsur.2024.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。